Machine Learning

A new partnership sees Veritone's AI unlock The Washington Post's video vault, aiming to monetize history while protecting journalistic integrity.

A new report reveals why distributors are holding more stock, risking cash flow to battle volatility and win customers in a fiercely competitive market.

The biotech firm accelerates a key trial but faces a partner loss, widening losses, and a CEO search, putting its promising siRNA pipeline at a crossroads.

With a total of $160M in Series B funding, Atavistik Bio is advancing its selective allosteric inhibitors for rare diseases HHT and MPNs.

Beating Wall Street estimates with historic gross profits, the chipmaker leverages new capital and key partnerships to push its ultra-low-power tech deeper into AI.

With a melanoma drug on track for 2027 and a deep pipeline, Immatics' 2025 net loss is part of a larger strategy to dominate PRAME cancer therapy.

With a new outpatient model, NexCure aims to bring life-saving cancer treatments like CAR-T closer to home, tackling a major healthcare bottleneck.

With mixed trial results for its obesity drug and rising costs, Skye Bioscience's upcoming 2025 earnings call is a pivotal moment for investors.

Kura Oncology's new AML drug, KOMZIFTI, sees rapid market uptake, strong financials, and an ambitious plan to reshape targeted cancer therapy.

Biotech firm Immunis, Inc. secures a promising drug candidate to treat a debilitating side effect of Parkinson's therapy, offering hope to millions.

As Singapore mandates e-invoicing, Cygnet.One leverages its global platform to simplify complex digital tax compliance for multinational enterprises.

Syntax Data launches Saidee, an AI that builds custom portfolios using proprietary, traceable data, aiming to solve key compliance fears for financial advisors.

Early data for zolucatetide shows it shrinks tumors in a rare genetic disease, cracking a long-undruggable cancer target and offering new hope.

Ad-tech giant Teads reports massive revenue growth post-merger, but a $352M impairment and restructuring signal deep integration challenges.

Following key acquisitions, the AI firm pivots to a vertically integrated defense powerhouse, forecasting explosive growth backed by a swelling order backlog.

With a new CEO known for scaling firms for acquisition, AI-native platform CYPHER Learning signals a major push for dominance in enterprise training.

A novel oral drug for Alzheimer's avoids a key side effect of current therapies, as its 'detangler' platform shows promise for Parkinson's and other diseases.

With $15M from top UAE families, TruDoc is scaling its 'hospital-at-home' model, signaling a major shift in how the GCC delivers critical care.

A Chinese firm's win at a top Korean battery expo signals a major shift in manufacturing tech, accelerating the path to cheaper, greener, solid-state batteries.

A Chinese firm's innovative probiotic packaging just won a top design award, solving a key industry problem and signaling a new era for 'Made in China'.